Eurofins Discovery Services North America, LLC

Eurofins Discovery Services North America, LLC, a foreign-owned contract research organization headquartered in St. Charles, Missouri, provides nonclinical laboratory research and development services to federal health, safety, and environmental agencies as a prime contractor on 99% of recent awards, competing predominantly in full-and-open procurements without set-aside designations.

The company's capability portfolio centers on receptor binding studies, predictive toxicology, safety pharmacology, analytical chemistry, microbiology, and in vitro screening assays supporting pharmaceutical development and chemical safety evaluation. Representative work includes a $6.17 million delivery order with the National Institute of Allergy and Infectious Diseases for preclinical models of infectious diseases, a $1.095 million NIAID order for interventional agents safety and pharmacokinetic services, and a $723.7 million FDA delivery order (running through September 2028) for non-clinical and laboratory support services. More recent work includes a $287,350 EPA modification for rescreening core reference chemicals in estrogen receptor and androgen receptor binding assays, and a $249,093 NIDA order for receptor profile screening under a Total Small Business set-aside.

Customer concentration sits heavily with the National Institutes of Health ecosystem. NIAID leads by potential value at $183.2 million across 19 awards (70% of combined potential value), followed by the FDA at $21 million (7 awards), NCATS at $18.2 million (12 awards), EPA's Office of Research and Development at $14.7 million (14 awards), and NIDA at $13.2 million (20 awards). These five customers account for 87% of award count and 96% of combined potential value. NIAID's dominance is anchored by a recent $50 million single-award indefinite-delivery contract awarded September 15, 2025, for interventional agents safety and pharmacokinetic services running through September 2032.

Eurofins holds four active indefinite-delivery vehicles: the $50 million NIAID IDC (awarded September 2025, services through September 2032), a $20 million FDA single-award IDC for research and development services (through September 2028), a $5 million NIDA single-award IDC for receptor binding and predictive toxicology (through September 2028, designated Total Small Business), and a $9.7 million EPA single-award IDC for in vitro and target-based assays (through December 2026). Under the Nonclinical Services for Development of Interventional Agents parent vehicle, Eurofins has executed 16 task orders carrying $12.1 million combined potential value. The EPA's indefinite-delivery vehicle 68HERC22D0008 has generated 10 task orders worth $3.1 million.

Award activity grew from eight in 2022 to thirteen in 2023 and eleven in 2024, then declined to four in 2025 and three in 2026. Within the next twenty-four months, five awards with combined potential value of $8.4 million reach ultimate completion and face recompete. Work is performed at facilities in St. Charles and St. Peters, Missouri, with additional locations including Weldon Spring, Missouri; Research Triangle Park, North Carolina; and France, depending on assay requirements and analytical capabilities. SCI-reportable invoiced revenue totaled $1.3 million in FY2024 with zero FTE trajectory reported across FY2022–FY2025, indicating that the majority of Eurofins' federal work occurs under indefinite-delivery vehicles where services are delivered as needed rather than through sustained staffing arrangements. The vendor operates as a 1% subcontractor (one sub award to Illumina, Inc. for mouse DNA isolation and assessment under an NCI task order in 2026) and does not rely on subcontractors for delivery on its prime work.

Eurofins Discovery Services North America, LLC is a subsidiary of Eurofins Discovery Services & Products US Holdings Inc., a foreign-owned parent entity. The company's specialization in nonclinical and laboratory support services to federal research and regulatory agencies, combined with its seat on multiple high-value indefinite-delivery vehicles with NIH components and the EPA, positions it as an established vendor in federal drug development and chemical safety evaluation markets.